Back to results
US 2019/0240345 A1Published application
Novel stable formulation
AssigneeBayer Pharma Aktiengesellschaft
InventorsCarsten OLBRICH, Thomas TRILL
Life of this patent
Estimating the term…
Abstract
The present invention relates to a stable formulation particularly suitable for the anti-mesothelin immunoconjugate MF-T-SPDB-DM4. The described stable aqueous formulation comprising MF-T-SPDB-DM4 is directly suitable for therapeutic applications and for subsequent lyophilization. The lyophilized powder can be reconstituted with water to create a reconstituted solution which is again suitable for therapeutic applications. It is a further object to provide a stable reconstituted protein formulation which is suitable for therapeutic administrations.
Claims10
An immunoconjugate formulation comprising:
- a. MF-T-SPDB-DM4;
- and
- b. one or more excipients selected from the group consisting of an amino acid, polysorbate 80, and sucrose;
- wherein the formulation is a buffered aqueous solution having a pH of 5.0 to 8.0
1 more element
Dependencies are inferred from the claim text.